Immuno-Oncology Assay Services

Based on an ever-growing panel of patient-derived micro-tumours (PDMs) with autologous TILs and PBMCs, we have established an advanced and versatile platform of CRO services for immuno-oncology (IO) testing studies of compounds, immuno-therapies and combination treatments.

We offer

    • Cell-based ex vivo studies with patient-derived micro-tumour models (PDMs) in co-cultures with autologous immune cells (from whole blood-derived PBMCs and/or tumour-derived TILs).

    • Full patient consent and FTO to perform commercial service-based studies.

    • In vitro co-culture assays of patient-derived 3D micro-tumours with immune cells from the same patients (e.g., PBMCs, antigen-specific T cells) for drug testing.

    • Performance of homogenous reader-based assays.

    • Quantification of cytotoxicity induced by immune cells (e.g. antigen-specific T cells) alone and in combination with standard-of-care or investigational compounds, immuno-therapies, oncolytic viruses, bi-specific antibodies, or combo treatments.

    • Live-cell confocal 3D analysis of microtumour infiltration by T lymphocytes.

    • Add-on protein assays, e.g. Luminex- and Simoa-based cytokine assays, or DigiWest pathway activity profiling

    • Fully customizable fee-for-service studies, and expertise from successful projects with numerous international pharmas.

 

References

  • PDM in Ovarian Cancer: Anderle N, et. al. Platform of Patient-Derived Microtumors Identifies Individual Treatment Responses and Therapeutic Vulnerabilities in Ovarian Cancer. Cancer (Basel) 2022

  • Potential of renal cell carcinoma PDMs and TILs for treatment response prediction: Erne E, et. al. Patient-derived microtumors: Potential for therapeutic response prediction-a case study. Urologie 2022

  • PDMs used for efficacy testing of novel combination treatment approaches in neurooncology:
    Przystal J M, et. al. Targeting CSF1R Alone or in Combination with PD1 in Experimental Glioma. Cancers (Basel) 2021
    Walter B, et. al. Argyrin F Treatment-Induced Vulnerabilities Lead to a Novel Combination Therapy in Experimental Glioma. Advanced Therapeutics 2021

Back to top